Skip to content
OpenCapital
Get started

Boston Scientific BSX Restricted cash equivalents included in Other long-term assets

Other financials

Income statement

See full
Revenue$5.2B+11.6%
Gross profit$3.6B+12.6%
Operating income$1.1B+19.5%
Net income$1.3B+99.3%
EPS (diluted)$0.90+100%

Balance sheet

See full
Cash & equivalents$850.0M+146%
Total equity$25.9B+16.4%
Total assets$44.4B+10.5%

Cash flow

See full
Operating cash flow$348.0M-35.7%
CapEx$177.0M-5.4%
Free cash flow$171.0M-51.7%

Valuation

See full
Market cap$67.32B-37.5%
P/E18.9×-34.3×
P/S3.3×-2.9×

Profitability

See full
Gross margin69.2%+0.5pp
Operating margin18.4%+2.2pp
Net margin17.3%+5.7pp

Returns & leverage

See full
Return on equity14.8%+5.2pp
Debt / equity0×-0.5×
Current ratio1.9×+0.4×

Where this comes from

Reported directly by Boston Scientific in its filing.

Tagged under the XBRL concept us-gaap:RestrictedCashEquivalentsNoncurrent.

The official record: Boston Scientific’s 10-Q, filed May 1, 2026, on SEC EDGAR. View the filing →

Ask your AI about Boston Scientific's restricted cash equivalents included in other long-term assets.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Boston Scientific's restricted cash equivalents included in other long-term assets?
Boston Scientific (BSX) reported restricted cash equivalents included in other long-term assets of $119M in Q1 2026.
How has Boston Scientific's restricted cash equivalents included in other long-term assets changed year-over-year?
Boston Scientific's restricted cash equivalents included in other long-term assets increased by 30.8% year-over-year, from $91M to $119M.
What is the long-term trend for Boston Scientific's restricted cash equivalents included in other long-term assets?
Over 4 years (2020 to 2024), Boston Scientific's restricted cash equivalents included in other long-term assets has grown at a 11.4% compound annual growth rate (CAGR), from $52M to $80M.